Why ACADIA Pharmaceuticals (ACAD) Stock Is Spiking Today

NEW YORK (TheStreet) -- ACADIA Pharmaceuticals (ACAD) shares are up 12.9% to $27.07 on Tuesday after the company announced that its Parkinson's disease psychosis treatment NUPLAZID was granted a Breakthrough Therapy designation from the FDA.

Drugs meeting the FDA Breakthrough Therapy requirements must treat life threatening diseases and should have preliminary clinical evidence demonstrating a substantial improvement over current treatment options.

The FDA reserves the right to expedite the review process for drugs meeting this criteria and ACADIA plans to submit the drug to the FDA for approval later this year.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates ACADIA PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate ACADIA PHARMACEUTICALS INC (ACAD) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

ACAD Chart ACAD data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

If you liked this article you might like

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?